P. R. Herzig & Company reduced its position in shares of Stryker Co. (NYSE:SYK) by 8.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The hedge fund owned 6,650 shares of the medical technology company’s stock after selling 650 shares during the period. Stryker comprises about 1.5% of P. R. Herzig & Company’s holdings, making the stock its 27th largest position. P. R. Herzig & Company’s holdings in Stryker were worth $618,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Capstone Asset Management Company boosted its stake in Stryker by 5.5% in the fourth quarter. Capstone Asset Management Company now owns 37,744 shares of the medical technology company’s stock worth $3,508,000 after buying an additional 1,956 shares during the period. CIBC World Markets boosted its stake in Stryker by 94.0% in the fourth quarter. CIBC World Markets now owns 15,327 shares of the medical technology company’s stock worth $1,424,000 after buying an additional 7,428 shares during the period. Atria Investments boosted its stake in Stryker by 67.7% in the fourth quarter. Atria Investments now owns 10,096 shares of the medical technology company’s stock worth $887,000 after buying an additional 4,075 shares during the period. CUE Financial Group boosted its stake in Stryker by 10.6% in the fourth quarter. CUE Financial Group now owns 9,434 shares of the medical technology company’s stock worth $877,000 after buying an additional 905 shares during the period. Finally, Gavekal Capital boosted its stake in Stryker by 12.1% in the fourth quarter. Gavekal Capital now owns 72,815 shares of the medical technology company’s stock worth $6,767,000 after buying an additional 7,886 shares during the period.

Stryker Co. (NYSE:SYK) opened at 93.91 on Monday. The company’s 50-day moving average price is $91.93 and its 200 day moving average price is $96.70. Stryker Co. has a 1-year low of $86.68 and a 1-year high of $105.34. The firm has a market cap of $35.27 billion and a price-to-earnings ratio of 30.60.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 22nd. The medical technology company reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.02. The firm had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.44 billion. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.15 earnings per share. On average, equities analysts expect that Stryker Co. will post $5.11 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Investors of record on Thursday, December 31st will be issued a dividend of $0.38 per share. The ex-dividend date is Tuesday, December 29th. This is a boost from Stryker’s previous quarterly dividend of $0.27. This represents a $1.52 annualized dividend and a yield of 1.62%.

A number of analysts have recently commented on the company. Citigroup Inc. assumed coverage on Stryker in a research report on Thursday, November 12th. They issued a “sell” rating and a $88.00 price objective for the company. Brean Capital restated a “hold” rating on shares of Stryker in a research report on Wednesday, January 13th. Zacks Investment Research cut Stryker from a “buy” rating to a “hold” rating in a research report on Tuesday, October 27th. Sterne Agee CRT started coverage on Stryker in a research report on Wednesday, November 4th. They set a “neutral” rating for the company. Finally, Needham & Company LLC cut Stryker to a “hold” rating in a research report on Tuesday, January 19th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $106.17.

In related news, Director Ronda E. Stryker sold 12,000 shares of Stryker stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $95.46, for a total transaction of $1,145,520.00. Following the completion of the transaction, the director now directly owns 183,694 shares of the company’s stock, valued at $17,535,429.24. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 6,000 shares of the firm’s stock in a transaction on Friday, November 13th. The stock was sold at an average price of $95.94, for a total value of $575,640.00. Following the transaction, the director now directly owns 183,694 shares of the company’s stock, valued at approximately $17,623,602.36. The disclosure for this sale can be found here.

Stryker Corporation is a medical technology company. The Company offers a range of products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine, which help improve patient and hospital outcomes.

12 Month Chart for NYSE:SYK

Receive News & Ratings for Stryker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Co. and related companies with MarketBeat.com's FREE daily email newsletter.